BioCentury | Dec 24, 2007
Company News

Cogentus board of directors update

Cogentus Pharmaceuticals Inc. , Menlo Park, Calif. Business: Gastrointestinal Appointed: Jide Zeitlin, founder of Keffi Group Ltd. WIR Staff Gastrointestinal...
BioCentury | Dec 24, 2007
Clinical News

CGT-2168: Phase III started

...evaluate aspirin plus CGT-2168 or Plavix clopidogrel from Bristol-Myers Squibb Co. (BMY, New York, N.Y.). Cogentus Pharmaceuticals Inc....
BioCentury | Dec 21, 2007
Financial News

Cogentus raises $62.5 million

...by the Keffi Group. Prospect Venture Partners; Ridgeback Capital; Apothecary; and Pinnacle Ventures also participated. Cogentus'...
...therapy. Bristol-Myers (BMY) and sanofi-aventis (Euronext:SAN; SNY) market Plavix clopidogrel. Keffi's Jide Zeitlin will join Cogentus'...
BioCentury | Dec 21, 2007
Financial News

Cogentus raises $62.5 million

...by the Keffi Group. Prospect Venture Partners; Ridgeback Capital; Apothecary; and Pinnacle Ventures also participated. Cogentus'...
...therapy. Bristol-Myers (BMY) and sanofi-aventis (Euronext:SAN; SNY) market Plavix clopidogrel. Keffi's Jide Zeitlin will join Cogentus'...
BioCentury | Nov 19, 2007
Clinical News

CGT-2168: Phase III start

...This quarter, Cogentus will begin a double-blind, international Phase III trial in 3,200 patients to evaluate...
...evaluate aspirin plus CGT-2168 or Plavix clopidogrel from Bristol-Myers Squibb Co. (BMY, New York, N.Y.). Cogentus Pharmaceuticals Inc....
Items per page:
1 - 5 of 5
BioCentury | Dec 24, 2007
Company News

Cogentus board of directors update

Cogentus Pharmaceuticals Inc. , Menlo Park, Calif. Business: Gastrointestinal Appointed: Jide Zeitlin, founder of Keffi Group Ltd. WIR Staff Gastrointestinal...
BioCentury | Dec 24, 2007
Clinical News

CGT-2168: Phase III started

...evaluate aspirin plus CGT-2168 or Plavix clopidogrel from Bristol-Myers Squibb Co. (BMY, New York, N.Y.). Cogentus Pharmaceuticals Inc....
BioCentury | Dec 21, 2007
Financial News

Cogentus raises $62.5 million

...by the Keffi Group. Prospect Venture Partners; Ridgeback Capital; Apothecary; and Pinnacle Ventures also participated. Cogentus'...
...therapy. Bristol-Myers (BMY) and sanofi-aventis (Euronext:SAN; SNY) market Plavix clopidogrel. Keffi's Jide Zeitlin will join Cogentus'...
BioCentury | Dec 21, 2007
Financial News

Cogentus raises $62.5 million

...by the Keffi Group. Prospect Venture Partners; Ridgeback Capital; Apothecary; and Pinnacle Ventures also participated. Cogentus'...
...therapy. Bristol-Myers (BMY) and sanofi-aventis (Euronext:SAN; SNY) market Plavix clopidogrel. Keffi's Jide Zeitlin will join Cogentus'...
BioCentury | Nov 19, 2007
Clinical News

CGT-2168: Phase III start

...This quarter, Cogentus will begin a double-blind, international Phase III trial in 3,200 patients to evaluate...
...evaluate aspirin plus CGT-2168 or Plavix clopidogrel from Bristol-Myers Squibb Co. (BMY, New York, N.Y.). Cogentus Pharmaceuticals Inc....
Items per page:
1 - 5 of 5